From genes to public health: The applications of genetic technology in disease prevention

American Journal of Public Health

Volumn 86, Issue 12, 1996, Pages 1717-1722

  Khoury, Muin J ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE TECHNOLOGY; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH CARE POLICY; HUMAN; PROPHYLAXIS; PUBLIC HEALTH; REVIEW;

GENETIC DISORDERS; GENETIC RESEARCH; GENETICS AND REPRODUCTION; HEALTH CARE AND PUBLIC HEALTH; HEALTH HAZARDS; HUMAN GENOME PROJECT; SOCIAL IMPACT; UNITED STATES;

ETHICS, MEDICAL; GENETIC DISEASES, INBORN; GENETIC RESEARCH; GENETIC SCREENING; GENETIC TECHNIQUES; HETEROZYGOTE DETECTION; HUMANS; PUBLIC HEALTH; UNITED STATES;

EID: 0030461680     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.86.12.1717     Document Type: Article

References (58)

1. Watson JD. The Human Genome Project: past, present and future. Science. 1990;248:44-49.
2. Jordan E. The Human Genome Project: where did it come from? Where is it going? Am J Hum Genet. 1992;51:1-6.
3. Hoffman EP. The evolving genome project: current and future impact. Am J Hum Genet. 1994;54:129-136.
4. Richards B, Skoletsky J, Shuber AP, et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993;2:159-163.
5. Suzuki D, Knudston P. Genethics: The Clash between the New Genetics and Human Values. Cambridge, Mass: Harvard University Press: 1989.
6. Holtzman NA. Proceed with Caution: Predicting Genetic Risks in the Recombinant DNA Era. Baltimore, Md: Johns Hopkins University Press; 1989.
7. Hubbard R, Wald E. Exploding the Gene Myth. Boston, Mass: Beacon Press; 1993.
8. Garver KL, Garver B. The Human Genome Project and eugenic concerns. Am J Hum Genet. 1994;54:148-158.
9. Schull WJ, Hanis CL. Genetics and public health in the 1990's. Annu Rev Public Health. 1990;11:105-125.
10. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of Genetic Epidemiology. New York, NY: Oxford University Press; 1993.
11. Institute of Medicine. The Future of Public Health. Washington, DC: National Academy Press; 1988.
12. McKusick VA. Mendelian Inheritance in Man: Catalogs of Autosomal Dominant, Autosomal Recessive, and X-Linked Phenotypes. 10th ed. Baltimore, Md: Johns Hopkins University Press; 1992.
13. McKusick VA, Amberger JS. The morbid anatomy of the human genome: chromosomal location of mutations causing disease. J Med Genet. 1994;31:265-279.
14. Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill Information Services Co; 1989.
15. King RA, Rotter JI, Motulsky AG. The Genetic Basis of Common Diseases. New York, NY: Oxford University Press; 1992.
16. Kalow W. Pharmacogenetics: past and future. Life Sci. 1990;47:1385-1397.
17. Grandjean P, ed. Ecogenetics: Genetic Predisposition to the Toxic Effects of Chemicals. New York, NY: Chapman and Hall; 1991.
18. Moutschen J. Introduction to Genetic Toxicology. New York. NY: John Wiley and Sons; 1985.
19. King MC, Rowell S, Love SM. Inherited breast and ovarian cancer: what are the risks? What are the choices? JAMA. 1993;269:1975-1980.
20. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene. Science. 1994;266:66-71.
21. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266:120-122.
22. Easton DF, Ford D, Bishop DT, et al. Breast and ovarian cancer incidence in BRCA1 mutation. Am J Hum Genet. 1995;56:265-271.
23. Salmon RJ, Vilcoq JR. Breast cancer after preventive subcutaneous mastectomy. Presse Med. 1995;24:1167-1168.
24. Decker D. Prophylactic mastectomy for familial breast cancer. JAMA. 1993;269:2608-2609.
25. Kaback MM, Lim-Steele D, Dabholkar D, et al. Tay-Sachs disease-carrier screening, prenatal diagnosis and the molecular era: an international perspective, 1970 to 1993. JAMA. 1993;270:2307-2315.
26. Shohat M, Legum C, Romem Y, et al. Down's syndrome prevention program in a population with an older maternal age. Obstet Gynecol. 1995;85:368-373.
27. Wald NJ, Densem JW, Smith D, Klee GG. Four-marker screening for Down's syndrome. Prenat Diagn. 1994;14:707-716.
28. US Public Health Service. Recommendation for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep. 1992;41:1-7.
29. Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects: implications for prevention. JAMA. 1995;274:1698-1702.
30. Oakley GP, Erickson JD, Adams MJ. Urgent need to increase folic acid consumption. JAMA. 1995;274:1717-1718.
31. Guthrie R. Newborn screening: past, present and future. In: Carter TP, Willey AM, Genetic Disease: Screening and Management. New York, NY: Alan R. Liss; 1986:317-342.
32. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314:1593-1599.
33. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402-1406.
34. Ely AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophiliac patients with factor VIII antibodies. Br J Haematol. 1990;76:238-241.
35. Khoury MJ, Newill CA, Chase GA. Epidemiologic evaluation of screening for risk factors: application to genetic screening. Am J Public Health. 1985;75:1204-1208.
36. Khoury MJ, Wagener DW. Epidemiologic evaluation of the use of genetics to improve the predictive value of disease risk factors. Am J Hum Genet. 1995;56:835-844.
37. Childs B, Motulsky AG. Recombinant DNA analysis of multifactorial disease. In: Childs B, Holtzman NA, Kazazian HH, Valle D, eds. Molecular Genetics in Medicine. New York, NY: Elsevier;1988:180-194.
38. Khoury MJ, Beaty TH. Applications of the case-control method in genetic epidemiology. Epidemiol Rev. 1994;16:134-150.
39. Wordsworth BP, Bell JI. The immunogenetics of rheumatoid arthritis. Springer Semin Immunopathol. 1992;14:59.
40. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992;117:801-806.
41. Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med. 1990;323:219.
42. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
43. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of the apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
44. Tsai MS, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer's disease. Am J Hum Genet. 1994;54:643-649.
45. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA. 1994;271:785.
46. Genetic Monitoring and Screening in the Workplace. Washington, DC: Office of Technology Assessment; 1990. OTA-Ba-455.
47. Schulte PA, Halperin WE. Genetic screening and monitoring for workers. In: Harrington JM, ed. Recent Advances in Occupational Health. Edinburgh, Scotland: Churchill Livingstone;1987:35-154.
48. Vineis P, Schulte PA. Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. J Clin Epidemiol. 1995;48:189-197.
49. Andrews LB, Jaeger AS. Confidentiality of genetic information in the workplace. Am J Law Med. 1991;17:75-108.
50. Billings PR, Beckwith J. Genetic testing in the workplace: a view from the USA. Trends Genet 1992;8:198-202.
51. Keverne EB. Molecular genetic approaches to understanding brain development and behavior. Psychoneuroendocrinology. 1994;19:407-414.
52. Plomin R, Owen MJ, McGuffin P. The genetic basis of complex human behaviors. Science. 1994;264:1733-1739.
53. Billings PR, Beckwith J, Alper JS. The genetic analysis of human behavior: a new era. Soc Sci Med. 1992;35:227-238.
54. Centers for Disease Control. A framework for assessing the effectiveness of disease and injury prevention. MMWR Morb Mortal Wkly Rep. 1992;41(Reports and Recommendations 3):1-13.
55. Berkelman RL, Curran JW. Epidemiology of HIV infection and AIDS. Epidemiol Rev. 1989;11:222-228.
56. Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Pediatrics. 1989;84:500-508.
57. Sickle Cell Guideline Panel. Sickle Cell Disease: Screening, Diagnosis, Management and Counseling in Newborns and Infants. Clinical Practice Guideline No. 6. Rockville, Md: Public Health Service, Agency for Health Care Policy and Research; April 1993. AHCPR publishing 93-0562.
58. Clinical Laboratory Improvement Act of 1988, 53 Federal Register 29590.